SEC Form 4 · accession 0001179110-17-005585
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew H Lane
Officer — Executive Vice President
Period of report
Apr 1, 2017
Accepted (ET)
Apr 4, 2017 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F1 | $44.36 | Apr 1, 2017 | A | 34,424 | A | Apr 1, 2018 | Mar 31, 2027 | Common shares | 34,424 | 34,424 | D |
Explanation of responses
- F1Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,475 on April 1, 2018, 11,474 on April 1, 2019, and 11,475 on April 1, 2020.